News
-
23.06.2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations - -
18.06.2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
| Manufacturing |
At our cGMP production facility, inspected by the United States Food and Drug Administration (FDA) and Swissmedic, we can produce small batches of drug products for feasibility studies, through clinical trial supplies onto commercial scale manufacturing. We have extensive experience with both small molecule pharmaceuticals and biologics. Throughout the entire chain, we develop, conduct and control production processes to ensure that our products conform to specifications and respect international Good Laboratory Practice (cGLP) and cGMP guidelines. |



